HHS’ Corrigan joins Arnold & Porter
Executive Summary
Former Acting HHS Inspector General Dara Corrigan joins Arnold & Porter as co-head, along with William Vodra, of the firm's drug and medical device practice group in the U.S. Corrigan was part of the Office of Inspector General's initial meetings with PBMs to learn more about their business practices in advance of the Medicare drug benefit (1"The Pink Sheet" March 29, 2004, p. 15). Corrigan had been the Centers for Medicare & Medicaid Services director of program integrity before moving to HHS' OIG to fill in after the resignation of Janet Rehnquist in 2003. General Services Administration Inspector General Daniel Levinson was tapped as permanent HHS IG in July...
You may also be interested in...
HHS Inspector General Meets With PBMs; Medco Explains “Transparency”
The HHS Office of the Inspector General is seeking to gain a better understanding of the pharmacy benefit management industry in advance of the Medicare prescription drug program
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.